EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Pharma AG decides on increase in share capital

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

20.07.2011

Ad-hoc release

SYGNIS Pharma AG decides on increase in share capital

Heidelberg, 20 July 2011 - Today the Management Board of the
Heidelberg-based SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard), with the approval of the Supervisory
Board, decided to increase the equity capital from euro 13,752,881
to up to euro 16,988,853, by issuing up to 3,235,972 no-par
value bearer shares from authorised capital. The new shares are to
be offered to the shareholders at a subscription price of euro 2.00
per new share.

The shareholders can subscribe to the new shares with dividend
rights from 1 April 2010 in a 17:4 ratio within the subscription
period which lasts from 26 July until 9 August 2011 (full days
included). Moreover, as part of an additional purchase existing
shareholders have the opportunity to subscribe for additional shares
which have not been subscribed by other shareholders.

In June 2011 dievini Hopp BioTech holding GmbH & Co. KG (dievini) has
committed financial funds of euro 6 million on the basis of a loan
agreement. Based on dievini´s commitment these funds shall be
invested within this capital increase in receipt of new shares worth
up to euro 6 million. Accordingly, the loan amount will be
reduced by the amount which dievini will invest as part of this
capital increase.

An organized trade in subscription rights will not occur. The
approval of the new shares for trading in the regulated
market (Prime Standard) at the Frankfurt Stock Exchange is not
expected before 17 August 2011. Further details of the capital
increase will be provided in the subscription offer expected to be
published in the electronic Federal Gazette (elektronischer
Bundesanzeiger) on 25 August 2011. The capital increase is
conducted by Landesbank Baden- Württemberg.

The proceeds are to be used for financing SYGNIS´ existing
operations, according to the present plans, at least until the
end of 2012 and in particular for the completion of the current
efficacy trial for AX200 for the treatment of acute stroke (AXIS
2) and the potential commercialization of this project.

For further information please contact:

|Dr. Franz-Werner Haas |
|Senior VP Operations |
|Tel: +49 (0) 6221-454 812 |
|Email: franz-Werner.haas@sygnis.de |

###
Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. The shares in SYGNIS Pharma
AG (the 'Shares') may not be offered or sold in the United States or to or for
the account or benefit of 'U.S. persons' (as such term is defined in Regulation
S under the U.S. Securities Act of 1933, as amended (the 'Securities Act')). No

offer or sale of transferable securities is being made to the public.
The shares are offered solely on the basis of subscription rights.
This document is only being distributed to and is only directed at
(i) persons who are outside the United Kingdom or (ii) to investment
professionals falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order')
or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within Article 49(2)(a) to (d) of
the Order (all such persons together being referred to as 'relevant
persons'). The Shares are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such
securities will be engaged in only with, relevant persons. Any person
who is not a relevant person should not act or rely on this document
or any of its contents.

Some statements included in this press release, relating neither to
proven financial results nor other historical data, should be viewed
as forward- looking, i.e. not definite. Such statements are mainly
predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English